Clinical Trials
10 trialsNCT03878095 2026-06-01
Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant Tumors
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT03682289 2026-04-23
Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
University of California, San Francisco
Phase 2 Active not recruiting
NCT03787680 2026-03-23
Targeting Resistant Prostate Cancer With ATR and PARP Inhibition (TRAP Trial)
University of Michigan Rogel Cancer Center
Phase 2 Active not recruiting
NCT03330847 2026-03-10
To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy.
AstraZeneca
Phase 2 Active not recruiting
NCT05941897 2026-03-05
LOTOS
AstraZeneca
Phase 2 Active not recruiting
NCT04417062 2026-02-25
Olaparib With Ceralasertib in Recurrent Osteosarcoma
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT04065269 2026-02-20
ATARI
Institute of Cancer Research, United Kingdom
Phase 2 Active not recruiting
NCT03579316 2026-02-18
Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT03334617 2025-10-27
HUDSON
AstraZeneca
Phase 2 Active not recruiting
NCT05061134 2025-07-31
MONETTE
AstraZeneca
Phase 2 Active not recruiting